https://www.live-feeds.com/feed/lilly-s-retatrutide-has-been-offered-to-a-single-person-via-compassionate-use-programContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/lilly-s-retatrutide-has-been-offered-to-a-single-person-via-compassionate-use-programhttps://www.live-feeds.com/feed/lilly-s-retatrutide-has-been-offered-to-a-single-person-via-compassionate-use-program#u15520Sat, 27 Jun 2026 08:16:19 +0000Eli Lilly and the FDA provided one unnamed 79-year-old man access to the unapproved obesity drug retatrutide in April 2026. This access was granted through a compassionate use program. The identity of the patient has led to public speculation and White House denials.What's confirmed:Eli Lilly and the FDA granted one 79-year-old man access to the unapproved drug retatrutide.The drug was provided through a compassionate use program.Access to the triple-agonist obesity drug was granted in April 2026.The White House denied that the application for the drug was filed for Donald Trump.Still unconfir